Company Filing History:
Years Active: 2018
Title: The Innovative Contributions of Nikolas Papadopoulos
Introduction
Nikolas Papadopoulos is a prominent inventor based in Towson, MD (US). He has made significant contributions to the field of cancer research, particularly in understanding pancreatic neuroendocrine tumors (PanNETs). His work has implications for both the scientific community and clinical practices.
Latest Patents
Nikolas Papadopoulos holds a patent titled "Genes frequently altered in pancreatic neuroendocrine tumors." This patent focuses on the genetic basis of PanNETs, which are a rare but clinically important form of pancreatic neoplasia. In his research, he determined the exomic sequences of ten non-familial PanNETs and screened the most commonly mutated genes in an additional 58 tumors. Remarkably, he found that 44% of the tumors had somatic inactivating mutations in MEN-1, which encodes menin, a component of a histone methyltransferase complex. Additionally, 43% of the tumors had mutations in genes encoding the two subunits of a transcription/chromatin remodeling complex consisting of DAXX and ATRX. Clinically, mutations in the MEN1 and DAXX/ATRX genes were associated with better prognosis. Furthermore, he discovered mutations in genes in the mTOR pathway in 14% of the tumors, which could potentially be used to stratify patients for treatment with mTOR inhibitors.
Career Highlights
Nikolas Papadopoulos is affiliated with The Johns Hopkins University, where he continues to advance research in cancer genetics. His work has garnered attention for its potential to improve patient outcomes through targeted therapies.
Collaborations
Nikolas has collaborated with notable figures in the field, including Bert Vogelstein and Kenneth W Kinzler. Their combined expertise has contributed to significant advancements in cancer research.
Conclusion
Nikolas Papadopoulos is a key figure in the study of pancreatic neuroendocrine tumors, with a patent that highlights the genetic alterations associated with this rare cancer. His work at The Johns Hopkins University and collaborations with esteemed colleagues underscore his commitment to advancing cancer research and improving patient care.